Timothy J. Daskivich

Jan 14, 2025 | urotoday.com | Timothy J. Daskivich

Read the Full Video TranscriptZachary Klaassen: My name is Zach Klaassen. I’m a Urologic Oncologist at the Georgia Cancer Center in Augusta, Georgia. I’m delighted to be joined here today by Dr. Tim Daskivich, who is a urologic oncologist at Cedars-Sinai Hospital in Los Angeles, California.Today, we’re going to be discussing Dr. Daskivich, his recent publication in JAMA Internal Medicine, overtreatment of prostate cancer among men with limited longevity in the active surveillance era.

Nov 11, 2024 | jamanetwork.com | Timothy J. Daskivich |Michael Luu |John Heard |I-Chun Thomas

Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era Key PointsQuestion  Is overtreatment of prostate cancer with definitive local therapy among men with limited life expectancy in the US Department of Veterans Affairs (VA) health system increasing in the active surveillance era?

Feb 22, 2024 | nature.com | Timothy J. Daskivich |Aurash Naser-Tavakolian |Nadine A. Friedrich |Howard M. Sandler

AbstractEffective communication of treatment side effects (SE) is critical for shared decision-making (SDM) in localized prostate cancer. We sought to qualitatively characterize how physicians communicate SE in consultations. We transcribed 50 initial prostate cancer treatment consultations across nine multidisciplinary providers (Urologists, Radiation Oncologists, Medical Oncologists) at our tertiary referral, academic center.